Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-02-11
2000-06-06
Higel, Floyd D.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
514378, 514400, 5483355, A61K 314164, A61K 3142, C07D23361, C07D26102
Patent
active
060720573
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a medical method of treatment employing the compounds and compositions. More particularly, this invention concerns 1H-4(5)-substituted imidazole derivatives and their salts or solvates. These compounds have H.sub.3 histamine receptor agonist activity. This invention also relates to pharmaceutical compositions containing these compounds, and to a method of treating disorders in which histamine H.sub.3 receptor activation is beneficial.
BACKGROUND OF THE INVENTION
Histamine is a chemical messenger involved in various complex biological actions. When released histamine interacts with specific macromolecular receptors on the cell surface or within a target cell to elicit changes in many different bodily functions. Various cell types including smooth muscle, blood cells, cells of the immune system, endocrine and exocrine cells as well as neurons respond to histamine by stimulating the formation of intracellular signals, including formation of phosphatidylinositol or adenylate cyclase. Evidence that histamine plays a role as a neurotransmitter was established by the mid to late 1970's (Schwartz, 1975) Life Sci. 17: 503-518. Immunohistochemical studies identified histaminergic cell bodies in the tuberomammillary nucleus of the posterior hypothalamus with widespread projections in the dicencephalon and telencephalon (Inagaki et al., 1988) J. Comp. Neurol. 273: 283-300.
Identification of two histamine receptors (H.sub.1 and H.sub.2) was reported to mediate the biochemical actions of histamine on neurons. Recently, studies have demonstrated the existence of a third subtype of histamine receptor, the histamine H.sub.3 receptor (Schwartz et al., 1986) TIPS 8: 24-28. Various studies have now demonstrated that histamine H.sub.3 receptors are found on the histaminergic nerve terminals in the brains of several species, including man (Arrang et al., 1983) Nature 302: 832-837. The H.sub.3 receptor found on the histaminergic nerve terminal was defined as an autoreceptor and could intimately control the amount of histamine released from the neurons. Histamine, the natural compound, was capable of stimulating this autoreceptor but when tested against known H.sub.1 and H.sub.2 receptor agonists and antagonists, a distinct pharmacological profile emerged. Further, H.sub.3 receptors have been identified on cholinergic, serotoninergic and monoamine nerve terminals in the peripheral nervous system (PNS) and central nervous system including the cerebral cortex and cerebral vessels. These observations suggest that H.sub.3 receptors are uniquely located to modulate histamine as well as other neurotransmitter release, and H.sub.3 agonists could be important mediators of neuronal activity.
As stated, CNS histaminergic cell bodies are found in the magnocellular nuclei of the hypothalamic mammillary region and these neurons project diffusely to large areas of the forebrain. The presence of histaminergic cell bodies in the tuberomamillary nucleus of the posterior hypothalamus, a brain area involved in the maintenance of wakefulness, and their projections to the cerebral cortex suggest a role in modulating the arousal state or sleep-wake cycle. The histaminergic projection to many limbic structures such as the hippocampal formation and the amygdaloid complex suggest roles in functions such as autonomic regulation, control of emotions and motivated behaviors, and memory processes.
The concept that histamine is important for the state of arousal, as suggested by the location of histaminergic pathways, is supported by other types of evidence. Lesions of the posterior hypothalamus is well known to produce sleep. Neurochemical and electrophysiological studies have also indicated that the activity of histaminergic neurons is maximal during periods of wakefulness and is suppressed by barbiturates and other hypnotics. Intraventricular histamine induces the appearances of an arousal EEG pattern in rabbits and in
REFERENCES:
patent: 3711495 (1973-01-01), Kulsa et al.
patent: 4080340 (1978-03-01), Kulsa et al.
patent: 4767778 (1988-08-01), Arrang et al.
patent: 4987146 (1991-01-01), Rohoe et al.
patent: 5156669 (1992-10-01), Zierke et al.
(Schwartz, 1975) Life Sci. 1.7: 503-518.
(Inagaki et al., 1988)J. Comp. Neurol. 273: 282-300.
(Schwartz et al., 1986) TIPS 8: 24-28.
(Arrang et al., 1983) Nature 302: 832-837.
(Lin et al., 1990) Brain Res. 529: 325-330.
S.M. Berge et a., "Pharmaceutical Salts," J. Pharm. Sci., 6.6: 1-19 (1977).
West et al., (1990) Mol. Pharmacol. 3.8 610-613.
Poste et al., "Lipid Vesicles as Carriers for Introducing Biologically Active Materials Into Cells," Chapter 4: 33-71.
Archiv der Parmazie (D 1358 E) Archiv der Pharmazie, (1973) Band 306: 933-940.
Khan Amin Mohammed
Phillips James G.
Tedford Clark E.
Gliatech Inc.
Higel Floyd D.
Katz, Esq. Martin L.
LandOfFree
1H-4(5)-cyclo-substituted imidazole derivatives as histamine H.s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1H-4(5)-cyclo-substituted imidazole derivatives as histamine H.s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1H-4(5)-cyclo-substituted imidazole derivatives as histamine H.s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2214602